Complix NV

Technologiepark 94

9052 Zwijnaarde

BE

Complix NV

Foundation date

23/06/2008

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.

Latest news

  • Antonin (Tony) de Fougerolles appointed as new Chair of etherna

    Tuesday July 16th 2024

  • ONTOFORCE Achieves ISO 27001:2022 Certification: A Milestone in Information Security and Trust

    Tuesday July 16th 2024

  • Ghent University spin-off Trince wins Nature Spinoff Prize

    Monday July 15th 2024